Certificate course for Speech-Language Pathologists in Bangalore: 24-26 NOv 2011

Dear Friends,

Here is an update from our friend Mr. Mathews from Five India:


It is with great excitement that i announce that the HANEN center has finally agreed to bring the It Takes Two To Talk ® to India  and FiVE has the honor of being their official hosts in India.


Testimonial : As an SLP working predominantly with younger children, I always believed that family had a larger role to play in the intervention process than just bringing the child to therapy. But the challenge of getting parents more actively involved was a hard one and so I was constantly online looking for resources I could use. That is when I found the Hanen Centre. On a first browse, I thought ‘Well, I am already trying out some of what they are suggesting’ but after a chat with a friend (in USA), who had just completed the It Takes Two to Talk course, I realized that what made it a brilliant program is IT’S STRUCTURE. It is so well laid out that you simply have to follow the steps and everything falls into place. The naturalistic approach makes the whole session fun for everyone involved (parents, caregivers, child and therapist). It is the Best thing that has happened to my work! It changed the way i think and the way i approach intervention. And it can also be easily incorporated into any environment of the child such as other therapy sessions (OT, PT, Special Education etc), school and with the whole family (not just parents).

Only 14 seats! Early bird registration closes on 20th August. For more details, please contact Sowmya on (+91)  9444407847




Mathew Easow




Now you can get Artificial Retina in the market

Artificial retina in European market

The world’s first artificial retina, Argus II, produced by U.S. company Second Sight Medical Products, was approved for sale in the European market. The
new product can give to people who have partially blind due to retinal degenerative diseases and will be available through several treatment centers in Europe, at a price of $ 100,000.

Artificial retina consists of several parts: a pair of glasses with a video camera sends images to a processing node, which in turn transforms images into
electrical impulses that are transmitted to an array of electrodes implanted in the retina of the wearer. The system offers a resolution of 60 pixels (picture
points), compared with tens of millions, he offers a healthy eye, but will allow users to discern shapes and distinguish light from dark.

The device was tested on 30 patients so far, and positive evaluations of European authorities led to the approval of the product for sale in Europe. Starting this summer, Argus II will be available at a price of $ 100,000 in
these medical centers:

* Centre Hospitalier National des Quinze-Vingts d’Ophthalmologie (Paris, France)
* Hôpitaux Universitaires de Genève (Geneva, Switzerland)
* Manchester Royal Eye Hospital (Manchester, United Kingdom)
* Moorfields Eye Hospital (London, UK).

Click here to read from Source: Human Store

Additional reading: Weekly Blitz

Hope or science? Multiple sclerosis surgical ‘procedure’ triggers debate

Pritha Chatterjee Posted online: Tue Jul 19 2011, 02:31 hrs

New Delhi : A debate has started over the use of a relatively new surgical procedure as treatment for Multiple Sclerosis (MS) in some hospitals in India. Critics say that the results are not scientifically established and the treatment not approved by regulatory authorities, but doctors are going ahead in the belief that MS, an autoimmune degenerative disorder, can be attributed to vascular reasons.At least three leading hospitals in different parts of the country have been offering the process, commonly known as ‘liberation therapy’, since June last year. At 170 cases, Medanta Medicity in Gurgaon has handled the largest number of cases. Fortis Hospital in Delhi is next with 38, followed by Apollo, Chennai, with around 12 patients.Based on Italian physician Dr Paolo Zamboni’s 2009 hypothesis that MS can be attributed to vascular reasons, hospitals argue that it should be treated the same way as in the case of blockages in the heart. Others point out that the long-term effects of such a surgery haven’t been established yet.

Dr Vipul Gupta, senior vascular surgeon at Medanta Medicity who has done a number of such procedures, says Medanta defines the procedure as an “internal study” since the treatment is not yet established, though patients are charged for the procedure.

“Implanting stents for vascular blockages is a routine procedure. Why does it have to be a special case for MS patients?” says Dr Ashok Chordiya, Director of Fortis Noida.

Dr Gupta identifies the condition as “Chronic Cerebrospinal Venous Insufficiency (CCSVI), where blockages caused by iron deposits in veins cut down the blood supply to the brain”. These deposits, he says, are surgically removed by balloon angioplasty, followed by the implantation of a stent. He claims about 30-40 per cent of patients at Medanta have shown short-term improvement.

According to a written statement from Fortis, no adverse effects have been reported so far.

But Dr V Balaji, senior consultant in vascular surgery at Apollo Chennai, who performed the first CCSVI procedure in India last April, admits that “patients say they feel good subjectively, but we have scientifically established only 0.5 per cent improvement in aspects like mobility and balance.” He adds that the demand for the therapy is high, even from abroad.

Patients who underwent the surgery have mixed responses. Surbhi Chichra, 35, underwent balloon angioplasty at a Noida hospital in June last year. A year later, Surbhi, now being treated at AIIMS, says, “after spending Rs 1.5 lakh for the procedure, my mobility has hit its lowest since I was first diagnosed with MS.”

Kavita Aggarwal, 38, also underwent the procedure last year. She says the hospital gave her a “slight ray of hope”, and that now that is gone.

But Teena Gera, 35, who got operated in February this year, says her perceptions of temperature have improved and she does not feel “so cold anymore”.

Says Dr M V Padma, Professor of Neurology at AIIMS, “Dr Zamboni’s study on 70-odd patients was without a control group. He could not establish that these vein blockages were a cause for MS. Till the treatment is proven and approved, it is not ethical to capitalise on the condition of helpless patients.”

Dr Anshu Rohatgi, consultant in neurology at Delhi’s Gangaram Hospital, says, “a study presented by the State University of New York at the American Academy of Neurology in April this year found that vein blockages were not a cause of MS.”

The disease

MS is a multifactoral disease, the precise cause of which remains unknown. The famyelin sheaths that cover nerves are damaged by the body’s immune system. Since 1995, disease-modifying drugs have been approved by the FDA for controlling the problem, but there is no established cure for MS — these drugs help manage and control it, delaying the onset of disability.

At least three leading hospitals in the country have been offering the ‘liberation therapy’ since June last year. At 170 cases, Medanta Medicity, Gurgaon, leads, followed by Fortis Hospital, Delhi, with 38 cases, and Apollo, Chennai, with 12.

source: Indian Express

Blind Persons can see with Bionic Eye

Dear Friends,

Bionic Eye or the “‘smart glasses” offers promise to Blind persons to now see. This technology called Argus II (Bionic Eye) developed by  Oxford University researchers,  uses a tiny camera and a pocket computer to alert users to the object and the person in front of him. These glasses will facilitate the visually impaired when they go shopping and to the train station. In fact, this tool can make the blind persons ‘read’ bus number and any digital display such as train numbers,  computer display on the ATM etc.

If the test is successful, these glasses can be found on the market in 2014. According to the Royal Society Summer Science Exhibition, the most important thing, the price is less than £ 1,000 and it will make these glasses can reach many people. Clinical neuro science researcher Dr. Stephen Hicks which received funding from the Ministry of Health said, “These glasses are very satisfactory and will be manufactured at a price that could reach everyone.” Currently, as reported Dailymail, Hicks claimed to have been working on prototype versions of these glasses.

<a href=”http://bit.ly/rbWQ1B&#8221; target=”_blank” />Check out this image!</a>